Skip to main content
Premium Trial:

Request an Annual Quote

Large Scale Biology to Expand Proteomics Facility

NEW YORK, Dec 7 - Large Scale Biology said Thursday that it expects to complete its new 53,000 sq ft proteomics facility in Germantown, Md., in the first quarter of 2001.

According to LSBC, the new facility will be the world's most highly automated center dedicated to quantitative proteomics.

The company plans to use the facility to extend its core proteomics platform, the ProGEx robotic system, and use it to create new database products for disease and drug effects. In a statement, Leigh Anderson, president of LSBC's proteomics subsidiary, noted that the ProGEx provides one million protein measurements per week.

“By the end of this year, we will have successfully completed the first version of the Human Protein Index, the protein equivalent of the human genome sequence,” Anderson said.

The facility will include ion trap mass spectrometry systems provided by Thermo Finnegan and MALDI MS systems provided by Bruker Daltonics  

" Proteomics is core to the discovery of breakthrough drug targets and disease markers for our partners, as well as to our internal development plans,” said Robert Erwin, CEO of LSBC, in a statement.  

The company was not immediately available for further comment.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.